Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study

  • GRELL EUROCARE-5 Working Group
  • Evaluative Epidemiology
  • IRCCS Fondazione Don Carlo Gnocchi - Milano
  • University of Granada
  • CIBER Epidemiologia y Salud Pública (CIBERESP)
  • Centre for Public Health
  • Queen's University Belfast
  • National Institute for Health
  • Head and Neck Cancer Medical Oncology Unit
  • Austrian CR
  • Tyrol CR
  • Belgian CR
  • Bulgarian CR
  • Croatian CR
  • Czech National CR
  • Danish Cancer Society
  • Estonian CR
  • Tallinn University of Technology
  • Finnish CR
  • Bas Rhin CR
  • Basse Normandie Haematological malignancies CR
  • Calvados Digestive Tract Registry
  • Calvados
  • Côte d'Or Digestive Tract Registry
  • Côte d’Or Gynaecologic CR
  • Côte d’Or Haematological Malignancies CR
  • Doubs CR
  • Finistère Digestive Tract Registry
  • Gironde CNS CR
  • Gironde Haematological Malignancies CR
  • Hérault CR
  • Hospices Civils de Lyon
  • Isere Cancer Registry (Grenoble)
  • Loire-Atlantique CR
  • Manche CR
  • MSA Marne Ardennes Meuse
  • Somme CR
  • Tarn CR
  • Bavaria CR
  • Berlin CR
  • Leibniz-Institut für Präventionsforschung und Epidemiologie
  • Deutsches Krebsforschungszentrum

Abstract

Background Head and neck (H&N) cancers are a heterogeneous group of malignancies, affecting various sites, with different prognoses. The aims of this study are to analyse survival for patients with H&N cancers in relation to tumour location, to assess the change in survival between European countries, and to investigate whether survival improved over time. Methods We analysed about 250,000 H&N cancer cases from 86 cancer registries (CRs). Relative survival (RS) was estimated by sex, age, country and stage. We described survival time trends over 1999-2007, using the period approach. Model based survival estimates of relative excess risks (RERs) of death were also provided by country, after adjusting for sex, age and sub-site. Results Five-year RS was the poorest for hypopharynx (25%) and the highest for larynx (59%). Outcome was significantly better in female than in male patients. In Europe, age-standardised 5-year survival remained stable from 1999-2001 to 2005-2007 for laryngeal cancer, while it increased for all the other H&N cancers. Five-year age-standardised RS was low in Eastern countries, 47% for larynx and 28% for all the other H&N cancers combined, and high in Ireland and the United Kingdom (UK), and Northern Europe (62% and 46%). Adjustment for sub-site narrowed the difference between countries. Fifty-four percent of patients was diagnosed at advanced stage (regional or metastatic). Five-year RS for localised cases ranged between 42% (hypopharynx) and 74% (larynx). Conclusions This study shows survival progresses during the study period. However, slightly more than half of patients were diagnosed with regional or metastatic disease at diagnosis. Early diagnosis and timely start of treatment are crucial to reduce the European gap to further improve H&N cancers outcome.

OriginalspracheEnglisch
ZeitschriftEuropean Journal of Cancer
Jahrgang51
Ausgabenummer15
Seiten (von - bis)2130-2143
Seitenumfang14
ISSN0959-8049
DOIs
PublikationsstatusVeröffentlicht - 01.10.2015

Fördermittel

Compagnia di San Paolo, Fondazione Cariplo Italy, Italian Ministry of Health (Ricerca Finalizzata 2009, RF-2009-1529710) and European Commission for two projects: (i) European Action Against Cancer, EPAAC, Joint Action No 20102202, and (ii) ‘Information network on rare cancers’, Grant No. 2000111201. The funding sources had no role in study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the article for publication.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen

Fingerprint

Untersuchen Sie die Forschungsthemen von „Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren